Disease | neuropathy |
Phenotype | C0009402|colorectal cancer |
Sentences | 10 |
PubMedID- 21444285 | Peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin. |
PubMedID- 22496202 | The present study investigated the occurrence of subclinical peripheral neuropathy in patients with colorectal cancer before the initiation of chemotherapy. |
PubMedID- 22865779 | Background: to report our prospective experience on the incidence and pattern of oxaliplatin (oxa)-induced peripheral neuropathy (oxa-ipn) in patients with colorectal cancer (crc) treated with either folfox-4 or xeloda + oxaliplatin (xelox). |
PubMedID- 25713534 | (2013) evaluated the efficacy of goshajinkigan for oxaliplatin-induced neuropathy in patients with colorectal cancer and demonstrated that goshajinkigan prevented exacerbation of neuropathy. |
PubMedID- 25183707 | A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. |
PubMedID- 24122404 | A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. |
PubMedID- 25627820 | We therefore conducted a multicenter randomized phase iii trial to compare fluorouracil, leucovorin, and oxaliplatin (mfolfox6) with and without goshajinkigan (gjg), a traditional japanese herbal medicine (kampo), to determine gjg's potential for reducing peripheral neuropathy in patients with colorectal cancer. |
PubMedID- 22154408 | Temporary interruption of oxaliplatin before limiting neurotoxicity develops during therapy is a potential approach to avoid the problem of oxaliplatin-associated neuropathy in patients with metastatic colorectal cancer. |
PubMedID- 25417732 | Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. |
PubMedID- 21814779 | Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. |
Page: 1